Title: Research and Development Scientific Leader
Company: GlaxoSmithKline (GSK)
Location: Collegeville, Pennsylvania, United States
Dr. Elizabeth Davenport, PhD, Research and Development Scientific Leader at GlaxoSmithKline (GSK), has been recognized by Marquis Who’s Who Top Scientists for dedication, achievements, and leadership in cell and molecular biology.
With more than 30 years of experience to her credit, Dr. Davenport most recently excelled as a research and development scientific leader in cell and gene therapy product development with GlaxoSmithKline (GSK) from 2018 to 2023. Prior to this position, in which her work on cell processes and stability enabled the launch of multiple T-cell therapy clinical trials, she was active with GSK as a postdoctoral fellow from 1994 to 1997, a cancer biology research investigator from 1997 to 2004, an assay development group leader from 2004 to 2015, and a discovery consultant from 2016 to 2017. She began her career as a postdoctoral fellow at the National Institute of Environmental Health Sciences from 1992 to 1994, during which time she studied organotypic cell culture. Notably, Dr. Davenport represented GSK as a health and wellness speaker at the 2018 Pennsylvania Conference for Women.
Before embarking on her professional path, Ms. Davenport pursued an education at Muhlenberg College, earning a Bachelor of Science in biology. She concluded her studies at Purdue University in 1991, graduating with a Doctor of Philosophy in cellular and molecular biology. Attributing her success to the coaches and mentors who guided her throughout her career, she was drawn to the world of biology during her freshman year of high school yet eventually pivoted to the pharmaceutical industry and oncology in order to make a difference in the lives of others. Among her most significant accomplishments, she is incredibly proud of her recent groundbreaking contributions involving the development of cell and gene therapy medicine for clinical trials to determine the safety and effectiveness of introducing this new form of therapy for eligible cancer patients. Looking toward the future, Dr. Davenport hopes to work with smart, energized people who are also committed to making a difference.
Contact Dr. Davenport: